MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study Cohorts

MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.82) by 9.76 percent. This is a 68.53 percent increase over losses of $(2.86) per share from the

8-K filing — MetaVia Inc. (MTVA)

Filed: 2026-07-09 AccNo: 0001104659-26-082116 Size: 324 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

MetaVia Files Prospectus For Offering $4M Common Shares